Content hub
Multi-year insights. Market-shifting forecasts. A clear view of what is next in rare diseases.
The top eight orphan drugs are projected to each surpass 6 billion dollars in global sales by 2032. Darzalex (daratumumab) leads the group, boosted by its subcutaneous formulation and an orphan‑focused change to the Inflation Reduction Act in 2025.
Darzalex helps secure Johnson & Johnson’s position as the leading orphan drug company, with nearly 31 billion dollars in expected sales in 2032. Argenx is also set to break into the top ten as the Vyvgart franchise grows toward 11 billion dollars in projected worldwide sales, placing the company ahead of Merck & Co. and Bristol Myers Squibb.
Explore previous editions
Rare disease strategy is shifting fast. Pricing frameworks, FDA expectations, competitive intensity, and investment patterns are all evolving at the same time. Many teams need more than data. They need a partner who can help them interpret the signals and move with confidence.
Evaluate’s Consulting and Analytics team provides tailored support for organizations that want to go deeper than the core report. Our consultants bring together Evaluate’s forecasting data, secondary research, custom modeling, and direct insight from key opinion leaders, healthcare professionals, and payers. The result is practical, evidence-based guidance that helps you navigate the most complex decisions in rare diseases.
Get in touch with our team to explore the right solutions for your business.
